Rockville, Maryland – October 30, 2026 New Fact.MR research shows the global dry eye syndrome treatment market expanding from USD 7.2 billion in 2026 to USD 12.9 billion by 2036, registering a 6.0% CAGR during the forecast period. The market is being shaped by rising dry eye prevalence, greater digital screen exposure, aging populations, environmental conditions, and broader access to pharmaceutical and device-based treatment options.

Get detailed market forecasts, competitive benchmarking, and pricing trends: 

Increasing awareness of dry eye disease as a chronic condition requiring clinical management is encouraging more patients to seek diagnosis and treatment. At the same time, anti-inflammatory prescription drops, biologics, intense pulsed light therapy, and meibomian gland expression are expanding treatment beyond conventional over-the-counter symptom relief. Growing adoption of in-office procedures is also creating additional treatment channels for ophthalmology and optometry practices.

Artificial Tears remain the leading product category, accounting for 42% of the product segment in 2026. Their broad availability, relatively low cost, and established role in first-line management of mild-to-moderate dry eye support continued demand. Within applications, Evaporative Dry Eye holds 48% of market value in 2026, reflecting the prevalence of meibomian gland dysfunction and lipid-layer deficiency as important contributors to dry eye symptoms.

India is projected to record the fastest country-level growth at an 8.0% CAGR through 2036, supported by increasing screen exposure, expanding ophthalmology infrastructure, and greater patient awareness. Germany is expected to grow at 5.8%, with its mature healthcare environment supporting adoption of premium prescription therapies and device-based procedures. The USA is forecast to expand at 5.5%, driven by high diagnosis rates, established prescription treatment adoption, and rising use of in-office device procedures.

The competitive landscape includes AbbVie (Allergan), Santen Pharmaceutical, Novartis AG (Alcon), Sun Pharmaceutical Industries, Bausch Health Companies, and Johnson & Johnson Vision. Competition spans prescription therapies, OTC artificial tears, and device-based treatment platforms, with pipeline development and procedural capabilities shaping market positioning.

With the market increasingly combining lubrication, prescription therapy, and in-office procedures, the full Fact.MR report provides detailed forecasts, segmentation, country analysis, and competitive insights for stakeholders evaluating the dry eye treatment opportunity through 2036.

Unlock 360° insights for strategic decision making and investment planning: 

Countries chosen: India for the highest country CAGR, Germany to represent Europe, and USA for a major mature healthcare market with established prescription and device-based treatment adoption.

Explore More Related Studies Published by Fact.MR Research

Plasmapheresis Market

Chromatography Syringes Market

Movement Disorder Market

About Fact.MR

Fact.MR is a market research and consulting firm providing syndicated research, customized research, investment research, and market intelligence across a broad range of industries. Its research coverage includes food and beverage, healthcare, pharmaceuticals, biotechnology, consumer products, chemicals and materials, technology, industrial goods, and packaging.

Fact.MR provides market intelligence designed to help organizations understand market dynamics, emerging opportunities, competitive developments, and changing industry requirements.

Media Contact

Fact.MR
Email: sales@factmr.com
Phone: +1 (628) 251-1583
Website: www.factmr.com